Cargando…

Risk of depression in multiple sclerosis across disease-modifying therapies

BACKGROUND: Depression and use of antidepressants are more common among patients with multiple sclerosis (MS) compared to the general population, but the relation of psychiatric comorbidity to use of different disease-modifying therapies (DMTs) is less clear. OBJECTIVE: To determine whether risk of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longinetti, Elisa, Frisell, Thomas, Englund, Simon, Reutfors, Johan, Fang, Fang, Piehl, Fredrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961249/ https://www.ncbi.nlm.nih.gov/pubmed/34264143 http://dx.doi.org/10.1177/13524585211031128

Ejemplares similares

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
por: Starvaggi Cucuzza, Chiara, et al.
Publicado: (2022)

Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
por: Fink, Katharina, et al.
Publicado: (2023)

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis
por: Longinetti, Elisa, et al.
Publicado: (2017)

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
por: Alping, Peter, et al.
Publicado: (2019)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Epidemiology of amyotrophic lateral sclerosis: an update of recent literature
por: Longinetti, Elisa, et al.
Publicado: (2019)

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls
por: Longinetti, Elisa, et al.
Publicado: (2022)

Risk factors for amyotrophic lateral sclerosis
por: Ingre, Caroline, et al.
Publicado: (2015)

Infections among individuals with multiple sclerosis, Alzheimer’s disease and Parkinson’s disease
por: Hu, Yihan, et al.
Publicado: (2023)

Creatinine and C-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease
por: Cui, Can, et al.
Publicado: (2020)

Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
por: Piehl, F.
Publicado: (2020)

Association of Infectious Mononucleosis in Childhood and Adolescence With Risk for a Subsequent Multiple Sclerosis Diagnosis Among Siblings
por: Xu, Yin, et al.
Publicado: (2021)

Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis
por: Brusini, Irene, et al.
Publicado: (2022)

Risk of serious infections in multiple sclerosis patients by disease course and disability status: Results from a Swedish register-based study
por: Brand, Judith S., et al.
Publicado: (2022)

Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis
por: Simonsen, Cecilia Smith, et al.
Publicado: (2016)

Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
por: Eriksson, Irene, et al.
Publicado: (2017)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Small noncoding RNA profiling across cellular and biofluid compartments and their implications for multiple sclerosis immunopathology
por: Zheleznyakova, Galina Yurevna, et al.
Publicado: (2021)

The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations
por: Eriksson, Irene, et al.
Publicado: (2018)

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Enlarged perivascular spaces in multiple sclerosis on magnetic resonance imaging: a systematic review and meta-analysis
por: Granberg, Tobias, et al.
Publicado: (2020)

Hospital-treated infections in early- and mid-life and risk of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis: A nationwide nested case-control study in Sweden
por: Sun, Jiangwei, et al.
Publicado: (2022)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis
por: Bergman, Petra, et al.
Publicado: (2016)

Response to electroconvulsive therapy in treatment-resistant depression: nationwide observational follow-up study
por: Nygren, Adam, et al.
Publicado: (2023)

Violent crime among Swedish military veterans after deployment to Afghanistan: a population-based matched cohort study
por: Pethrus, Carl-Martin, et al.
Publicado: (2019)

Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis
por: Cui, Can, et al.
Publicado: (2022)

Inflammation-related plasma and CSF biomarkers for multiple sclerosis
por: Huang, Jesse, et al.
Publicado: (2020)

Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study
por: Smith, Kelsi A, et al.
Publicado: (2023)

Gender Perspective of Risk Factors Associated with Disclosure of HIV Status, a Cross-Sectional Study in Soweto, South Africa
por: Longinetti, Elisa, et al.
Publicado: (2014)

Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data
por: Barbulescu, Andrei, et al.
Publicado: (2022)

New oral disease-modifying therapies for multiple sclerosis
por: Bagert, Bridget A, et al.
Publicado: (2009)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Disease-modifying therapies in multiple sclerosis in Latin America
por: Skromne-Eisenberg, Eli, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_la01el8ljh88lg7gi298j2asfi